Correction of increased prostacyclin synthesis in Bartter's syndrome by indomethacin treatment.
The role of prostacyclin and thromboxane A2 in the pathogenesis of Bartter's syndrome was investigated by measurement of the urinary excretion of 6-keto-PGF1 alpha and thromboxane B2, respectively, in five patients. The prostaglandin metabolites were extracted from urine by a reproducible method and measured by specific radioimmunoassays. The patients with Bartter's syndrome excreted about four-times as much 6-keto-PGF1 alpha as the normal controls. In contrast, there was no significant difference in the urinary excretion of thromboxane B2 between the patients and the controls. In a second part of the study, three patients were treated with indomethacin (150 mg/day for four days), an inhibitor of prostaglandin synthesis. This regimen suppressed urinary excretion of 6-keto-PGF1 alpha by 43% and that of thromboxane B2 by 46%. It is suggested that the increase in prostacyclin production is responsible for both the hyperreninemia and and the other endocrine derangements as well as the hyporesponsiveness of blood pressure to intravenous infusion of vasopressors in patients with Bartter's syndrome.
D015121:6-Ketoprostaglandin F1 alpha; D000293:Adolescent; D000328:Adult; D001477:Bartter Syndrome / Q000652:urine*; D002648:Child; D011464:Epoprostenol / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000652:urine*; D007213:Indomethacin; D008875:Middle Aged; D011453:Prostaglandins / Q000096:biosynthesis*; D011458:Prostaglandins E / Q000652:urine*; D011460:Prostaglandins F / Q000652:urine*; D012016:Reference Values; D013929:Thromboxane B2 / Q000652:urine*; D013931:Thromboxanes / Q000652:urine*
D011453:Prostaglandins; D011458:Prostaglandins E; D011460:Prostaglandins F; D013931:Thromboxanes; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D007213:Indomethacin